Trials / Completed
CompletedNCT03826134
A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects
Interventional, Phase I, Open-label, First in Human, Single-center Positron Emission Tomography (PET) Study Investigating Test-retest Properties of [11C]-PXT012253 as a Radiotracer in Healthy Subjects
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This study evaluates the usefulness of a PET radioligand to estimate the binding on the mGlu4 receptor in the brain. mGlu4 has been proposed as a therapeutic target in Parkinson's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [11C]PXT012253 | Single intravenous bolus injection. The injected amount will be less than 5 μg. The radioactive dose is approximately 400 MBq per 70 kg body weight. |
Timeline
- Start date
- 2019-01-17
- Primary completion
- 2019-03-15
- Completion
- 2019-03-15
- First posted
- 2019-02-01
- Last updated
- 2020-02-05
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT03826134. Inclusion in this directory is not an endorsement.